Shattuck Labs, Inc. (STTK)

Market Cap	114.43M
Revenue (ttm)	32.03M
Net Income (ttm)	-61.46M
Shares Out	42.38M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	342,602
Open	2.75
Previous Close	2.76
Day's Range	2.63 - 2.87
52-Week Range	2.55 - 20.95
Beta	n/a
Analysts	Buy
Price Target	19.18 (+610.4%)
Earnings Date	Nov 7, 2022

About STTK

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

• Industry: Biotechnology
• IPO Date: Oct 9, 2020
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: STTK

Full Company Profile

Financial Performance

In 2021, Shattuck Labs's revenue was $30.02 million, an increase of 202.16% compared to the previous year's $9.93 million. Losses were -$44.97 million, 22.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for STTK stock is "Buy." The 12-month stock price forecast is 19.18, which is an increase of 610.37% from the latest price.

Price Target

$19.18

(610.37% upside)

Analyst Consensus: Buy

Stock Forecasts